

Mechanisms of Immune-Related Adverse Events Kim A. Margolin, MD *City of Hope*







Society for Immunotherapy of Cancer

Association of Community Cancer Centers



Disclosures

- Amgen Inc., Lion Biotechnologies, Inc., Pfizer, Consulting Fees
- I *will not* be discussing non-FDA approved indications during my presentation.





Outline


- Basic principles of immunological tolerance and autoimmunity
- Differential roles of CTLA-4 and PD-1 in maintenance of tolerance
- Mechanisms of breakdown of tolerance by checkpoint blockade







Major Effector Cells of the Immune System





Most Autoimmune Diseases are due to Failure of T cell Tolerance


Immunologic Tolerance: unresponsiveness of immune system to self antigens







As a reminder...



MHC = Major Histocompatibility Complex

also called the HLA (human leukocyte antigen) complex










HLA (or MHC) is the strongest genetic factor for susceptibility to autoimmune disease

HLA- and gender-associated risk for autoimmune disease			
Disease	HLA allele	Relative risk	Sex ratio (♀:♂)
Ankylosing spondylitis	B27	87.4	0.3
Type 1 diabetes	DQ2 and DQ8	~25	~1
Goodpasture's syndrome	DR2	15.9	~1
Pemphigus vulgaris	DR4	14.4	~1
Autoimmune uveitis	B27	10	<0.5
Psoriasis vulgaris	CW6	7	~1
Systemic lupus erythematosus	DR3	5.8	10–20
Addison's disease	DR3	5	~13
Multiple sclerosis	DR2	4.8	10
Rheumatoid arthritis	DR4	4.2	3
Graves' disease	DR3	3.7	4–5
Hashimoto's thyroiditis	DR5	3.2	4–5
Myasthenia gravis	DR3	2.5	~1
Type I diabetes	DQ6	0.02	~1

Figure 15.37 Janeway's Immunobiology, 9th ed. (© Garland Science 2017)

Central and Peripheral Tolerance




Central Tolerance

- For T cells it occurs in the thymus
- Fate of high affinity, self-reactive T cells is death (deletion) and removal from T cell pool
- Some survive as regulatory (supp<mark>res</mark>sor) T cells while others escape to peripheral tissues


Peripheral Tolerance

Self-reactive T cells are suppressed by regulatory T cells
CTLA-4 and PD-1, among other molecules play a role in maintaining selfreactive T cells from becoming activated (anergic)


Peripheral tolerance occurs in the absence of CD28 dependent co-stimulation




CTLA-4 inhibits co-stimulation by blocking interaction between CD28 and B7 molecules



Anti-CTLA-4 can lead to breakdown of peripheral tolerance by restoring co-stimulation




Breakdown of peripheral tolerance leading to activation of self-reactive T cells Regulatory T cells (Tregs) use CTLA-4 to remove B7 molecules from surface of antigen presenting cells to prevent activation of self reactive T cells




Anti-CTLA-4 (ipilimumab) may interfere with inhibitory function of Tregs

Inhibitory receptors provide a second mechanism for maintenance of tolerance




Interaction of PD-1 with its ligands, PD-L1/PD-L2 inhibits CD28 signaling in T cells

- PD-1 is upregulated on T cells after activation
- PD-L1 is found on both immune and non-immune cells in peripheral tissues
- PD-L2 is mostly found on immune cells in response to inflammatory stimuli
- In contrast, CTLA-4 and its ligands are only found on immune cells
- Mice deficient in PD-1 have delayed development of autoimmune disease compared to CTLA-4 deficient ones



Blocking PD-1/PD-L1 Pathway Reactivates T cells

<u>PD-1</u> is the receptor on T cells – its ligand <u>PD-L1 is on immune cells or tumor</u> cells




Polymorphisms in CTLA-4 and PD-1 genes have been linked to human autoimmune diseases

Autoimmune Disease	Polymorphism
Thyroiditis, Graves' disease, Hashimoto's disease	CTLA-4
Diabetes mellitus	CTLA-4
Celiac disease	CTLA-4
Myasthenia gravis	CTLA-4
Lupus	CTLA-4; PD-1
Rheumatoid Arthritis	CTLA-4; PD-1
Addison's disease	CTLA-4


Adapted from Michot JM, et al ; European Journal of Cancer; 2016; 54:139


People with CTLA-4 haploinsufficiency develop a spectrum of autoimmune diseases similar to the irAEs observed with ipilimumab




Early and late irAEs may occur by distinct mechanisms

Early and common





Late and rare



Breakdown of organ specific tolerance

Activation of tumor specific T cells that recognize antigen shared between tumor and healthy tissue: vitiligo, myocarditis

Activation of tissue specific anergic T cells that recognize antigen distinct from the tumor

T cell or antibody mediated tissue destruction

Summary: CTLA-4 and PD-1 are important in maintenance of peripheral immune tolerance

- CTLA-4 expression on effector and regulatory T cells prevents co-stimulation through CD28 and maintains T cell anergy and peripheral tolerance
- Activation of PD-1 on activated T cells by its ligands renders them non-functional
- PD-1 activates regulatory T cells to maintain peripheral tolerance
- Humans with CTLA-4 haploinsufficiency develop a spectrum of autoimmune manifestations similar to irAEs seen after treatment with Ipilimumab